Lexaria Bioscience (LEXX)
(Delayed Data from NSDQ)
$2.79 USD
-0.02 (-0.71%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $2.73 -0.06 (-2.15%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LEXX 2.79 -0.02(-0.71%)
Will LEXX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LEXX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for LEXX
7 A-Rated Penny Stocks to Beat June Gloom
Lexaria Bioscience awards CRO contract for DehydraTECH GLP-1 human study
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
7 A-Rated Biotech Stocks Worth Betting on in June
Lexaria Bioscience continues dosing in second GLP-1 human pilot study